Last reviewed 2026-04-19 · How we verify

Malignant Melanoma with BRAF V600E Mutation

Approved treatments

• Tybost · Gilead Sciences
  Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications.
• Tafinlar · Novartis
  Tafinlar blocks the activity of a mutated protein called BRAF that is involved in cancer cell growth.
• Zelboraf · Hoffmann La Roche
  Zelboraf blocks the activity of the B-raf protein, which is involved in cell growth and division.
• Mekinist · Novartis
  Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells.
• Zelboraf · Hoffmann-La Roche

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Malignant Melanoma with BRAF V600E Mutation patent landscape — cliff calendar, originator estates, attackable patents
• Malignant Melanoma with BRAF V600E Mutation treatment landscape brief
• Malignant Melanoma with BRAF V600E Mutation treatment updates RSS

Frequently asked questions about Malignant Melanoma with BRAF V600E Mutation

Related

• Treatment landscape: Malignant Melanoma with BRAF V600E Mutation patent cliff · Malignant Melanoma with BRAF V600E Mutation CI report
• Treatment: Tybost · Gilead Sciences
• Treatment: Tafinlar · Novartis
• Treatment: Zelboraf · Hoffmann La Roche
• Treatment: Mekinist · Novartis
• Treatment: Zelboraf · Hoffmann-La Roche
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing